News
ASRT
0.5945
-2.60%
-0.0159
Weekly Report: what happened at ASRT last week (0414-0418)?
Weekly Report · 1d ago
Weekly Report: what happened at ASRT last week (0407-0411)?
Weekly Report · 04/14 11:08
Weekly Report: what happened at ASRT last week (0331-0404)?
Weekly Report · 04/07 11:08
Weekly Report: what happened at ASRT last week (0324-0328)?
Weekly Report · 03/31 11:18
Weekly Report: what happened at ASRT last week (0317-0321)?
Weekly Report · 03/24 11:07
Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025
Barchart · 03/20 08:10
Assertio Holdings Price Target Cut to $3.50/Share From $4.00 by HC Wainwright & Co.
Dow Jones · 03/19 10:59
Assertio Holdings Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/19 10:59
HC Wainwright & Co. Maintains Buy on Assertio Holdings, Lowers Price Target to $3.5
Benzinga · 03/19 10:50
ASSERTIO HOLDINGS, INC. <ASRT.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $3.5 FROM $4
Reuters · 03/19 10:10
U.S. RESEARCH ROUNDUP-AT&T, Brighthouse Financial, ETSY
Reuters · 03/19 07:35
Weekly Report: what happened at ASRT last week (0310-0314)?
Weekly Report · 03/17 11:17
ASSERTIO HOLDINGS, INC. FORM 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024
Press release · 03/12 21:46
Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/12 21:20
*Assertio Holdings Sees 2025 Sales $108M-$123M >ASRT
Dow Jones · 03/12 20:17
*Assertio Holdings 4Q Adj Loss/Shr 3c >ASRT
Dow Jones · 03/12 20:17
Assertio Holdings Non-GAAP EPS of -$0.03 misses by $0.04, revenue of $32.1M beats by $3.43M
Seeking Alpha · 03/12 20:15
ASSERTIO HOLDINGS INC OUTLOOK 2025 NET PRODUCT SALES $108.0 MILLION TO $123.0 MILLION
Reuters · 03/12 20:05
ASSERTIO HOLDINGS, INC. Q4 NET INCOME USD -10.5 MILLION
Reuters · 03/12 20:05
*Assertio Holdings 4Q Rev $32.2M >ASRT
Dow Jones · 03/12 20:05
More
Webull provides a variety of real-time ASRT stock news. You can receive the latest news about Assertio Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About ASRT
More
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Recently
Symbol
Price
%Change